Breast Cancer Update

Featuring perspectives from Dr David W Cescon, including the following topics:

• Clinical treatment of BRCA-mutated metastatic triple-negative breast cancer (0:00)
• CNS activity of TROP2-directed antibody-drug conjugates (5:36)
• Autoimmune considerations with immunotherapy (10:09)
• Treatment of oligoprogressive advanced breast cancer (17:31)

CME information and select publications

Featuring perspectives from Dr David W Cescon, including the following topics:

• First-line treatment of metastatic triple-negative breast cancer (mTNBC) in patients not eligible for immunotherapy (0:00)
• First-line treatment of mTNBC in patients eligible for immunotherapy (12:05)
• Adverse events (19:39)

CME information and select publications

Featuring perspectives from Dr Aditya Bardia, Dr Kevin Kalinsky and Dr Joyce O'Shaughnessy, including the following topics:

• Introduction (0:00)
• Hormone Receptor-Positive Breast Cancer — Dr Kalinsky (1:18)
• HER2-Positive Breast Cancer — Dr Bardia (42:46)
• Triple-Negative Breast Cancer — Dr O'Shaughnessy (1:01:41)

CME information and select publications

Featuring perspectives from Dr Lisa A Carey and Dr Maha Hussain, including the following topics:

• Introduction (0:00)
• HER2 History (1:32)
• Cases from the GMO Survey (7:06)
• Biology and Selection of First-Line Therapy for HR-Positive, HER2-Positive Metastatic Breast Cancer (mBC) — Dr Mahtani (19:56)
• Faculty Case Presentations (31:37)
• Patterns of Care Survey — Part 1 (38:26)
• Optimizing the Use of Up-Front Maintenance Therapy for HER2-Positive mBC — Dr Carey (44:53)
• Faculty Case Presentations (54:13)

CME information and select publications

Featuring perspectives from Prof Peter Schmid and Dr Melinda Telli, including the following topics:

• Introduction: TROP2-Targeting Antibody-Drug Conjugates (ADCs) for Metastatic Triple-Negative Breast Cancer (0:00)
• First-Line Therapy (PD-L1 Negative) (6:53)
• First-Line Therapy (PD-L1 Positive) (23:40)
• Second-Line Therapy (Sequencing) (34:08)
• Adverse Events with TROP2-Targeting ADCs (43:43)

CME information and select publications

Featuring perspectives from Dr Virginia Kaklamani and Dr Hope S Rugo, including the following topics:

• Introduction: San Antonio Memories (0:00)
• PI3K/AKT/PTEN Alterations and Therapies (7:18)
• Capivasertib (20:22)
• Gedatolisib (34:08)
• Inavolisib (47:07)
• New Agents and Ongoing Trials (52:34)

CME information and select publications

Featuring perspectives from Ms Blanca Ledezma, Dr Marissa Marti-Smith, Dr Heather McArthur and Dr Ruth M O'Regan, moderated by Dr McArthur, including the following topics:

• Introduction (0:00)
• Current Clinical Role of Oral Selective Estrogen Receptor Degraders (SERDs) in HR-Positive Metastatic Breast Cancer (3:37)
• Practical Considerations with Oral SERDs (15:42)
• Potential Role of Combination Approaches with Oral SERDs (26:31)
• Gastrointestinal Adverse Events Documented with Oral SERDs (38:17)
• Potential Role of Early Therapeutic Switching After Detection of an Emergent ESR1 Mutation (46:51)
• Other Class-Effect Toxicities Associated with Oral SERDs (1:00:53)
• Emerging Utility of Adjuvant Oral SERDs (1:10:16)
• Unique Toxicities Associated with 1 or More Oral SERDs (1:19:17)

CME information and select publications

Featuring perspectives from Dr Reva Basho, Ms Kelly Fischer, Ms Melissa Rikal and Dr Seth Wander, moderated by Dr Wander, including the following topics:

• Introduction (00:00)
• Identification of Appropriate Candidates for Agents Targeting the PI3K/AKT/mTOR Pathway (3:45)
• Role of Inavolisib in HR-Positive Metastatic Breast Cancer (mBC) (13:00)
• Strategies to Prevent and Manage Hyperglycemia (27:02)
• Clinical Utility of Capivasertib for HR-Positive mBC (38:09)
• Mitigation and Management of Gastrointestinal Adverse Events (51:05)
• Management of Dermatologic Adverse Events (59:58)
• Potential Role of Gedatolisib in the Management of HR-Positive mBC (1:08:42)
• Monitoring and Management of Cytopenias (1:21:23)

CME information and select publications

Featuring perspectives from Ms Kelly Fischer, Dr Marissa Marti-Smith, Dr Rita Nanda and Dr Ruth M O'Regan, moderated by Dr Nanda, including the following topics:

• Introduction (00:00)
• Advent of CDK4/6 Inhibitors in HR-Positive Breast Cancer (BC) (1:24)
• Risk Assessment for Patients with HR-Positive, HER2-Negative Localized BC (2:52)
• Adjuvant CDK4/6 Inhibitor Therapy (17:14)
• Practical Considerations with CDK4/6 Inhibitors (29:57)
• Monitoring and Management of Cytopenias (42:02)
• CDK4/6 Inhibitors in HR-Positive Metastatic BC (49:32)
• Management of Gastrointestinal Adverse Events (1:03:47)
• CDK4/6 Inhibitors in Unique Populations (1:10:41)
• Rarer CDK4/6 Inhibitor-Associated Toxicities (1:19:48)

CME information and select publications

Featuring perspectives from Dr Sara A Hurvitz, Dr Erica Mayer, Dr Joyce O’Shaughnessy, Dr Sara M Tolaney and Dr Nicholas Turner, moderated by Dr Tolaney, including the following topics:

• Introduction (0:00)
• Current and Future Roles of Agents Targeting the PI3K/AKT/mTOR Pathway and Oral Selective Estrogen Receptor Degraders (SERDs) in First-Line Therapy for HR-Positive, HER2-Negative Metastatic Breast Cancer (mBC) — Dr Turner (2:35)
• Role of Oral SERD Monotherapy in the Treatment of Progressive HR-Positive, HER2-Negative mBC — Dr O’Shaughnessy (25:23)
• Potential Use of Oral SERD-Containing Combination Regimens in Managing Progressive HR-Positive, HER2-Negative mBC — Dr Mayer (46:29)
• Clinical Utility of Agents Targeting the PI3K/AKT/mTOR Pathway for Patients with Progressive HR-Positive, HER2-Negative mBC — Dr Hurvitz (1:07:06)
• Potential Use of Oral SERDs for HR-Positive, HER2-Negative Localized Breast Cancer — Dr Tolaney (1:38:17)

CME information and select publications